🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

We’ve updated our IR blog (Japanese only) －IRブログを更新しました： 「 ニューロクライン社のムスカリン作動薬に関するアップデート」 bit.ly/41EFhXz

We’ve updated our IR blog (Japanese only) －IRブログを更新しました：「TMP-301のフェーズ2試験の開始が発表されました」　bit.ly/4hL4Egn

Our partner Tempero Bio has initiated a Phase 2 trial of TMP-301, a potent, selective and orally available mGluR5 negative allosteric modulator (NAM), for the treatment of alcohol use disorder. Read more here: ssl4.eir-parts.net/doc/4565/tdnet…

We’re excited to share the appointment of Mr. Kiyoshi Kaneko as Chief Commercial Officer. Mr. Kaneko brings experience in business development, corporate strategy, marketing and commercial roles within the pharmaceutical and healthcare industries in Japan. ssl4.eir-parts.net/doc/4565/ir_ma…

We’re pleased to announce that Mariko Nakafuji has been promoted to Chief Legal Officer. Mariko joined Nxera in 2021 as General Counsel and has since played a key role in several strategic projects. ssl4.eir-parts.net/doc/4565/ir_ma…

We’ve updated our IR blog (Japanese only) －IRブログを更新しました：「Pfizer社がDanuglipronの開発を中止しました」 bit.ly/4juMr7N

We’re delighted to welcome Shinya Tsuzuki as our new Head of Investor Relations. Shinya brings deep sector insight and strong relationships across the investor community in Japan and internationally, and joins at a pivotal time in our growth journey. ssl4.eir-parts.net/doc/4565/ir_ma…

Our partner Neurocrine Biosciences has initiated a Phase 3 registrational study of NBI-‘568 as a potential treatment for adults with #schizophrenia – the first NxWave™-designed molecule to enter a Phase 3 trial. Read more here: ssl4.eir-parts.net/doc/4565/tdnet…

We’ve updated our IR blog (Japanese only) －IRブログを更新しました：「ニューロクライン社がM4作動薬のP3試験開始を報告」　bit.ly/3Sla5bf

We’ve updated our IR blog (Japanese only) －IRブログを更新しました：「個人投資家様向けサイトの新設」　bit.ly/4346h3s

We’ve just published our Q1 2025 results. One year on since our transformation to Nxera Pharma, we’re proud to report significant operational and financial progress. Full announcement here: ssl4.eir-parts.net/doc/4565/tdnet…

We’ve updated our IR blog (Japanese only) －IRブログを更新しました：「2025年12月期の第1四半期決算を発表しました」　bit.ly/3ShB7jS

We’ve updated our IR blog (Japanese only) －IRブログを更新しました：「ニューロクライン社、ファイザー社の決算が発表されました」　bit.ly/3Yu9dor

We’ve updated our IR blog (Japanese only) －IRブログを更新しました：「1Q決算後の機関投資家との対話」　bit.ly/3GY1dWA

We’ve updated our IR blog (Japanese only) －IRブログを更新しました：「塩野義製薬の決算が発表されました」　bit.ly/4j462Lz

We’re proud to be sponsoring the 4th Annual GPCRs-Targeted Drug Discovery Summit taking place in Boston next week. Our Vice President and Head of Platform Technology, Stacey Southall, will be presenting on Wednesday 21st May – learn more: gpcrs-drugdiscovery.com #DrugDiscovery

We’ve updated our IR blog (Japanese only) －IRブログを更新しました：「Endpoints News主催のドラッグロス解消を目指すオンラインイベントに登壇しました」　bit.ly/4dyhNZJ

Our CEO, Chris Cargill, and COO, Toshi Maeda, spoke with Mark Swallow for the Endpoints News / Nikkei Biotechnology and Business webinar "Taking the next steps with your drug in Japan". Register to watch the webinar on demand here: events.endpts.com/japan-biotech25

We’ve updated our IR blog (Japanese only) －IRブログを更新しました：「ニューロクライン社がM4作動薬NBI-1117568のP2試験結果をASCP2025で発表しました」　bit.ly/3Z3jYhN

We’ve updated our IR blog (Japanese only) －IRブログを更新しました：「Eli Lillyとの代謝性疾患を対象とした提携において開発マイルストンを達成」　 bit.ly/4jrgtZF